Cervical response to vaccination against HPV16 E7 in case of severe dysplasia.
OBJECTIVE
To evaluate the tolerance to vaccination against human papillomavirus (HPV)16 E7 (in SB adjuvant ASO2B) and its histological and immunohistological effects on HPV16 associated high-grade cervical dysplasias associated with HPV16.


METHODS
Five patients with histologically demonstrated severe cervical dysplasia (CIN3) HPV16 positive were injected three times before conization was performed 2 months after the first injection. We studied cytological, histological, proliferative pattern and immune profile before and after vaccination. The slides were compared with those obtained from non-injected patients.


RESULTS
The injections were well tolerated and the specimens displayed a limited regression of the lesions. Nevertheless, massive CD4 and CD8 T cell lymphocytic infiltration was noticed after vaccination.


CONCLUSIONS
We conclude that the vaccination we used provides an obvious immune histological reaction in the HPV infected cervix and that the 2 months delay before the final step (conization) is done is probably too short.
Simon
Ph
P
Department of Obstetrics and Gynaecology, CUB Hopital Erasme, Route de Lennik 808, 1070 Brussels, Belgium. psimon@ulb.ac.be
Buxant
F
F
Hallez
S
S
Burny
A
A
Fayt
I
I
Anaf
V
V
Noël
J C
JC
D000293:Adolescent; D000328:Adult; D018949:Antigens, CD1 / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002584:Cervix Uteri / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology*; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000276:immunology / Q000628:therapy*; D012074:Remission Induction / Q000379:methods; D002578:Uterine Cervical Dysplasia / Q000276:immunology / Q000473:pathology / Q000601:surgery / Q000628:therapy* / Q000821:virology*; D014611:Vaccination / Q000379:methods
D018949:Antigens, CD1; C419393:CD1a antigen; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; C059731:oncogene protein E7, Human papillomavirus type 16